InkVivo Technologies secures CHF 1.1 million in pre-seed funding to enhance its innovative polymer drug delivery platform.
Target Company Overview
InkVivo Technologies is a pioneering Swiss biotech startup that emerged from ETH Zurich and is currently incubated at the USI Startup Centre in Lugano. The company has recently secured CHF 1.1 million in pre-seed funding, which will facilitate the development of its innovative polymer drug delivery systems and expedite their commercialization.
The funds raised will primarily be allocated towards advancing the clinical development of InkVivo’s advanced polymer-based drug delivery formulations. Furthermore, the investment will enable the company to expand its product pipeline across various therapeutic areas.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Switzerland
The Swiss biotechnology industry is recognized for its robust innovation and strong positioning within the global market. With a highly skilled workforce, t
Similar Deals
TiVentures and Claves Investments
invested in
InkVivo Technologies
in 2025
in a Pre-Seed Stage deal
Disclosed details
Transaction Size: $1M